Membership
PrecisionCardio™ is member-governed. Companies do more than fund PrecisionCardio: they surface what they are seeing, determine the shared priorities, and contribute the expertise that moves the work forward.
Biotechnology and pharmaceutical companies.
Membership is designed for therapeutics companies working across precision cardiovascular medicine.
Professional societies, patient organizations, academic institutions, clinicians and other experts participate as strategic partners or collaborators when their expertise is relevant to a member-selected priority. They are not a second class of membership.
Members support PrecisionCardio through annual dues and take part in its governance and program of work.
Members set the agenda.
Members bring forward recurring observations from across diseases, specialties and care settings.
Members determine which issues become shared priorities through PrecisionCardio's governance process.
A member-led working group forms around the priority, bringing in the relevant external expertise and strategic partners as needed.
The group determines the appropriate collective action: professional-society collaboration, educational initiatives, practical resources, academic partnerships, shared gap analysis or other pre-competitive work.
PrecisionCardio does not begin with a fixed roster of outside organizations.
Members determine the question first, then bring in the professional society, patient organization, academic group, clinical experts or other partners that particular work needs.
Member-led by design.
PrecisionCardio is governed by its members and Board of Directors. The Board provides fiduciary and organizational oversight, while members help set priorities and participate in the work through PrecisionCardio's governance structure and working groups.
Surface what they are seeing. Determine the shared priorities.
Fiduciary and organizational oversight. Forming with the founding membership.
One per priority, with the partners the work needs.
Detailed voting, committee and governance provisions are contained in the Alliance's governing documents and membership materials.
At the disease level, the challenge is shared.
Product-specific decisions are not.
PrecisionCardio does not coordinate product-specific clinical development, regulatory or commercial strategy, product positioning, pricing, contracting, market allocation or other competitively sensitive activity. Educational and scientific content is developed independently of member companies. Alliance activities will operate under appropriate antitrust and compliance procedures.
Founding membership is now forming.
Founding members will help shape PrecisionCardio's initial priorities, governance and first program of work.
Founding membershipNow forming · Open through December 2026
Membership
We are forming the founding member group now. Founding members will have an early chance to shape PrecisionCardio’s agenda for 2027.
Open through December 31, 2026
Biotech and pharma companies in precision cardiovascular medicine.
Professional societies, patient organizations, academic centers, and clinicians join individual projects as partners. They are not a membership tier.
An early voice in the 2027 agenda.
Founding members will help choose the first shared priorities, take part in the first working groups, and have input on governance as the board forms. Members fund the work through annual dues.
What happens next.
Founding conversations with therapeutics companies
Founding membership closes
Members vote on the first program of work
At the disease level, the challenge is shared.
Product-specific decisions are not.
We do not coordinate clinical development, regulatory or commercial strategy, positioning, pricing, contracting, market allocation, or other competitively sensitive activity. Educational and scientific content is developed independently of member companies. All activities follow antitrust and compliance procedures.
Want to talk about founding membership?
Start a membership conversationStart a conversation